Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for NovaBay Pharmaceuticals (NBY) over the last 13 years, with Q3 2025 value amounting to $479000.0.

  • NovaBay Pharmaceuticals' Cost of Revenue changed N/A to $479000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 7816.43%. This contributed to the annual value of $4.0 million for FY2024, which is 1426.14% down from last year.
  • According to the latest figures from Q3 2025, NovaBay Pharmaceuticals' Cost of Revenue is $479000.0.
  • NovaBay Pharmaceuticals' Cost of Revenue's 5-year high stood at $4.0 million during Q4 2024, with a 5-year trough of $479000.0 in Q3 2025.
  • In the last 5 years, NovaBay Pharmaceuticals' Cost of Revenue had a median value of $1.8 million in 2021 and averaged $1.7 million.
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' Cost of Revenue plummeted by 4680.08% in 2023, and later skyrocketed by 29127.06% in 2024.
  • NovaBay Pharmaceuticals' Cost of Revenue (Quarter) stood at $2.2 million in 2021, then fell by 9.9% to $1.9 million in 2022, then crashed by 46.8% to $1.0 million in 2023, then skyrocketed by 291.27% to $4.0 million in 2024, then tumbled by 88.13% to $479000.0 in 2025.
  • Its Cost of Revenue was $479000.0 in Q3 2025, compared to $4.0 million in Q4 2024 and $1.0 million in Q2 2024.